Therapeutic Drug Monitoring
Patient Selection
- Therapeutic drug monitoring is recommended for patients with borderline renal function, but not routinely necessary for patients with GFR >50 mL/min, according to the Infectious Diseases Society of America 1
- For patients with normal renal function (creatinine clearance >80 mL/min), the standard dose of levofloxacin 250-500 mg once daily can be administered without dose adjustment, as recommended by the Infectious Diseases Society of America guidelines 2
- Dose adjustment for levofloxacin is required when creatinine clearance falls below 50-80 mL/min, with specific recommendations for different creatinine clearance levels, according to the HIV Medicine Association of the Infectious Diseases Society of America guidelines 2
- For patients with creatinine clearance >50-80 mL/min, a 500-mg loading dose, then 250 mg q24h is recommended, while for those with creatinine clearance <50 mL/min, a 500-mg loading dose, then 250 mg q48h is recommended, as per the Infectious Diseases Society of America guidelines 2
- The American Thoracic Society/CDC/IDSA guidelines note that insufficient data exist to guide dosing recommendations for patients with a reduced but >30 mL/min creatinine clearance, and in such patients, standard doses are used by experts 1
- Regular monitoring of renal function during treatment is necessary, as levofloxacin can potentially cause further renal impairment 1
- Therapeutic drug monitoring can be considered in patients with borderline renal function, measuring serum concentrations 2 and 6 hours after administration to optimize dosing, as recommended by the American Thoracic Society/CDC/IDSA guidelines 1
Dosing Recommendations
- The following dosing recommendations are suggested:
| Creatinine Clearance | Dosing Recommendation |
|---|---|
| >80 mL/min | Standard dose, 250-500 mg once daily |
| 50-80 mL/min | 500-mg loading dose, then 250 mg q24h |
| <50 mL/min | 500-mg loading dose, then 250 mg q48h |
Renal Function Monitoring
- Regular monitoring of renal function during treatment is necessary to minimize the risk of renal impairment, as recommended by the American Thoracic Society/CDC/IDSA guidelines 1